Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ORCHPHARMANSE
Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 4% | 22% | 23% | -12% |
| - | - | -40% | -92% |
| - | 19% | 19% | 11% |
| -22% | 4% | 7% | 1% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
ORCHPHARMA
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 964.95 | ₹5692 Cr | 132.42 | 4.77 | 13.9 | ₹10 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹341 Cr | ₹304 Cr | ₹238 Cr | ₹207 Cr | ₹298 Cr | ₹263 Cr | ₹237 Cr | ₹217 Cr | ₹223 Cr | ₹244 Cr | ₹217 Cr | ₹221 Cr | ₹199 Cr | ₹183 Cr | ₹210 Cr | ₹160 Cr | ₹165 Cr | ₹131 Cr | ₹178 Cr | ₹161 Cr | ₹128 Cr | ₹92 Cr | ₹120 Cr | ₹103 Cr | ₹109 Cr | ₹119 Cr | ₹112 Cr | ₹129 Cr | ₹132 Cr | ₹135 Cr | ₹497 Cr | ₹479 Cr | ₹360 Cr | ₹336 Cr | ₹310 Cr | ₹252 Cr | ₹213 Cr |
| ₹18 Cr | ₹2 Cr | ₹7 Cr | ₹6 Cr | ₹12 Cr | ₹12 Cr | ₹4 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹13 Cr | ₹8 Cr | ₹8 Cr | ₹2 Cr | ₹2 Cr | ₹9 Cr | ₹6 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹11 Cr | ₹2 Cr | ₹93 L | ₹1 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹5 Cr | ₹0 | ₹3 L | ₹0 | ₹1 L | ₹18 Cr | ₹53 Cr | ₹75 L |
| ₹359 Cr | ₹306 Cr | ₹245 Cr | ₹213 Cr | ₹310 Cr | ₹275 Cr | ₹241 Cr | ₹226 Cr | ₹230 Cr | ₹252 Cr | ₹230 Cr | ₹228 Cr | ₹207 Cr | ₹185 Cr | ₹212 Cr | ₹169 Cr | ₹171 Cr | ₹134 Cr | ₹180 Cr | ₹164 Cr | ₹130 Cr | ₹95 Cr | ₹131 Cr | ₹105 Cr | ₹109 Cr | ₹120 Cr | ₹117 Cr | ₹136 Cr | ₹138 Cr | ₹141 Cr | ₹497 Cr | ₹479 Cr | ₹360 Cr | ₹336 Cr | ₹328 Cr | ₹305 Cr | ₹213 Cr |
| ₹329 Cr | ₹301 Cr | ₹220 Cr | ₹215 Cr | ₹306 Cr | ₹279 Cr | ₹218 Cr | ₹200 Cr | ₹201 Cr | ₹220 Cr | ₹197 Cr | ₹194 Cr | ₹183 Cr | ₹168 Cr | ₹177 Cr | ₹154 Cr | ₹165 Cr | ₹140 Cr | ₹179 Cr | ₹168 Cr | ₹137 Cr | ₹113 Cr | ₹122 Cr | ₹137 Cr | ₹121 Cr | ₹130 Cr | ₹155 Cr | ₹161 Cr | ₹164 Cr | ₹179 Cr | ₹406 Cr | ₹380 Cr | ₹328 Cr | ₹268 Cr | ₹273 Cr | ₹215 Cr | ₹177 Cr |
| ₹42 Cr | ₹16 Cr | ₹34 Cr | ₹7 Cr | ₹15 Cr | ₹6 Cr | ₹32 Cr | ₹35 Cr | ₹38 Cr | ₹40 Cr | ₹42 Cr | ₹43 Cr | ₹32 Cr | ₹24 Cr | ₹41 Cr | ₹23 Cr | ₹24 Cr | ₹15 Cr | ₹28 Cr | ₹16 Cr | ₹13 Cr | ₹3 Cr | ₹29 Cr | -₹3 Cr | ₹19 Cr | ₹21 Cr | -₹7 Cr | ₹7 Cr | ₹6 Cr | -₹7 Cr | ₹129 Cr | ₹131 Cr | ₹72 Cr | ₹101 Cr | ₹87 Cr | ₹114 Cr | ₹56 Cr |
| ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr | ₹8 Cr | ₹4 Cr | ₹7 Cr | ₹10 Cr | ₹11 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹14 Cr | ₹78 L | ₹3 Cr | ₹9 L | ₹0 | ₹50 Cr | ₹27 Cr | ₹54 Cr | ₹38 Cr | ₹30 Cr | ₹17 Cr | ₹22 Cr |
| ₹27 Cr | ₹3 Cr | ₹23 Cr | -₹12 Cr | ₹1 Cr | -₹7 Cr | ₹19 Cr | ₹22 Cr | ₹26 Cr | ₹28 Cr | ₹30 Cr | ₹30 Cr | ₹20 Cr | ₹11 Cr | ₹66 Cr | ₹7 Cr | -₹3 Cr | -₹14 Cr | -₹4 Cr | -₹11 Cr | -₹17 Cr | -₹28 Cr | -₹3 Cr | -₹45 Cr | -₹24 Cr | -₹23 Cr | -₹39 Cr | -₹28 Cr | -₹26 Cr | -₹38 Cr | -₹8 Cr | ₹76 Cr | -₹17 Cr | -₹1 Cr | -₹34 Cr | ₹73 Cr | ₹14 Cr |
| ₹27 Cr | ₹3 Cr | ₹23 Cr | -₹12 Cr | ₹1 Cr | -₹7 Cr | ₹19 Cr | ₹22 Cr | ₹26 Cr | ₹28 Cr | ₹34 Cr | ₹30 Cr | ₹20 Cr | ₹11 Cr | ₹59 Cr | ₹7 Cr | -₹3 Cr | -₹14 Cr | -₹5 Cr | -₹14 Cr | ₹49 Cr | -₹31 Cr | -₹25 Cr | -₹45 Cr | -₹24 Cr | -₹23 Cr | -₹39 Cr | -₹28 Cr | -₹26 Cr | -₹38 Cr | -₹11 Cr | ₹57 Cr | -₹19 Cr | -₹5 Cr | -₹34 Cr | ₹49 Cr | ₹11 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Trade Payables
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Sep 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 | Mar 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹15 Cr | ₹15 Cr | ₹51 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹89 Cr | ₹89 Cr | ₹89 Cr | ₹89 Cr | ₹85 Cr | ₹70 Cr | ₹70 Cr | ₹70 Cr | ₹70 Cr | ₹70 Cr | ₹66 Cr | ₹66 Cr | ₹65 Cr |
| ₹45 Cr | ₹45 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹96,000 | ₹0 |
| ₹1504 Cr | ₹1494 Cr | ₹1119 Cr | ₹648 Cr | ₹607 Cr | ₹612 Cr | ₹725 Cr | -₹793 Cr | -₹881 Cr | -₹477 Cr | -₹40 Cr | ₹244 Cr | ₹310 Cr | ₹1062 Cr | ₹999 Cr | ₹867 Cr | ₹563 Cr | ₹599 Cr | ₹419 Cr | ₹711 Cr |
| ₹1504 Cr | ₹1494 Cr | ₹1119 Cr | ₹648 Cr | ₹607 Cr | ₹612 Cr | ₹725 Cr | -₹793 Cr | -₹881 Cr | -₹477 Cr | -₹40 Cr | ₹244 Cr | ₹310 Cr | ₹1062 Cr | ₹999 Cr | ₹867 Cr | ₹563 Cr | ₹599 Cr | ₹419 Cr | ₹711 Cr |
| ₹1564 Cr | ₹1554 Cr | ₹1169 Cr | ₹689 Cr | ₹647 Cr | ₹653 Cr | ₹766 Cr | -₹704 Cr | -₹792 Cr | -₹388 Cr | ₹49 Cr | ₹329 Cr | ₹380 Cr | ₹1132 Cr | ₹1069 Cr | ₹938 Cr | ₹634 Cr | ₹665 Cr | ₹485 Cr | ₹776 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹62 L | ₹3 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹185 Cr | ₹3 L | ₹22 L | ₹40 Cr | ₹111 Cr | ₹342 Cr | ₹430 Cr | ₹1425 Cr | ₹1894 Cr | ₹2157 Cr | ₹2378 Cr | ₹2494 Cr | ₹902 Cr | ₹1074 Cr | ₹604 Cr | ₹1036 Cr | ₹1714 Cr | ₹980 Cr | ₹707 Cr | ₹843 Cr |
| ₹0 | ₹10 Cr | ₹120 Cr | ₹109 Cr | ₹97 Cr | ₹86 Cr | ₹74 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹625 Cr | ₹902 Cr | ₹991 Cr | ₹942 Cr | ₹202 Cr |
| -₹29 L | -₹10 L | ₹0 | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹46 Cr | ₹94 Cr | ₹111 Cr | ₹157 Cr | ₹170 Cr | ₹194 Cr | ₹203 Cr | ₹128 Cr | ₹115 Cr | ₹92 Cr | ₹80 Cr |
| ₹5 Cr | ₹4 L | ₹37 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹42 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹13 Cr | ₹5 Cr | ₹4 Cr | ₹13 Cr | ₹11 Cr | ₹12 Cr | ₹12 Cr | ₹8 Cr | ₹7 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹8 Cr | ₹10 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹203 Cr | ₹15 Cr | ₹124 Cr | ₹165 Cr | ₹222 Cr | ₹442 Cr | ₹519 Cr | ₹1436 Cr | ₹1905 Cr | ₹2205 Cr | ₹2475 Cr | ₹2609 Cr | ₹1064 Cr | ₹1252 Cr | ₹850 Cr | ₹1864 Cr | ₹2744 Cr | ₹2085 Cr | ₹1741 Cr | ₹1125 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹347 Cr | ₹336 Cr | ₹230 Cr | ₹174 Cr | ₹168 Cr | ₹110 Cr | ₹102 Cr | ₹302 Cr | ₹359 Cr | ₹425 Cr | ₹374 Cr | ₹311 Cr | ₹597 Cr | ₹447 Cr | ₹335 Cr | ₹318 Cr | ₹390 Cr | ₹296 Cr | ₹235 Cr | ₹216 Cr |
| ₹56 Cr | ₹27 Cr | ₹14 Cr | ₹53 Cr | ₹47 Cr | ₹26 Cr | ₹70 Cr | ₹1344 Cr | ₹958 Cr | ₹476 Cr | ₹285 Cr | ₹113 Cr | ₹1053 Cr | ₹407 Cr | ₹1005 Cr | ₹294 Cr | ₹369 Cr | ₹359 Cr | ₹389 Cr | ₹23 Cr |
| ₹88 Cr | ₹143 Cr | ₹14 Cr | ₹141 Cr | ₹23 Cr | ₹3 Cr | ₹0 | ₹695 Cr | ₹694 Cr | ₹600 Cr | ₹634 Cr | ₹647 Cr | ₹1525 Cr | ₹647 Cr | ₹490 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹80 L | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹1 Cr | ₹40 Cr | ₹44 Cr | ₹52 Cr | ₹31 Cr | ₹50 Cr | ₹159 Cr | ₹360 Cr | ₹97 Cr | ₹78 Cr | ₹42 Cr | ₹30 Cr |
| ₹491 Cr | ₹509 Cr | ₹260 Cr | ₹372 Cr | ₹241 Cr | ₹142 Cr | ₹175 Cr | ₹2346 Cr | ₹2013 Cr | ₹1541 Cr | ₹1338 Cr | ₹1123 Cr | ₹3206 Cr | ₹1551 Cr | ₹1989 Cr | ₹972 Cr | ₹856 Cr | ₹734 Cr | ₹665 Cr | ₹268 Cr |
| ₹2258 Cr | ₹2077 Cr | ₹1554 Cr | ₹1225 Cr | ₹1111 Cr | ₹1237 Cr | ₹1460 Cr | ₹3077 Cr | ₹3125 Cr | ₹3358 Cr | ₹3862 Cr | ₹4061 Cr | ₹4651 Cr | ₹3938 Cr | ₹3910 Cr | ₹3774 Cr | ₹4234 Cr | ₹3484 Cr | ₹2891 Cr | ₹2169 Cr |
| ₹25 Cr | ₹18 Cr | ₹57 Cr | ₹42 Cr | ₹43 Cr | ₹45 Cr | ₹0 | ₹143 Cr | ₹162 Cr | ₹141 Cr | ₹71 Cr | ₹107 Cr | ₹168 Cr | ₹531 Cr | ₹322 Cr | ₹405 Cr | ₹365 Cr | ₹385 Cr | ₹269 Cr | ₹303 Cr |
| ₹301 Cr | ₹153 Cr | ₹134 Cr | ₹331 Cr | ₹268 Cr | ₹453 Cr | ₹566 Cr | ₹3230 Cr | ₹3202 Cr | ₹3106 Cr | ₹3215 Cr | ₹3211 Cr | ₹3204 Cr | ₹2005 Cr | ₹2079 Cr | ₹1661 Cr | ₹2616 Cr | ₹1971 Cr | ₹1649 Cr | ₹1045 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹1517 Cr | ₹1499 Cr | ₹1301 Cr | ₹1221 Cr | ₹1176 Cr | ₹1176 Cr | ₹1247 Cr | ₹1520 Cr | ₹1519 Cr | ₹3006 Cr | ₹3006 Cr | ₹3002 Cr | ₹3772 Cr | ₹3090 Cr | ₹2614 Cr | ₹2345 Cr | ₹2696 Cr | ₹2098 Cr | ₹1563 Cr | ₹1364 Cr |
| ₹825 Cr | ₹791 Cr | ₹681 Cr | ₹647 Cr | ₹593 Cr | ₹506 Cr | ₹389 Cr | ₹263 Cr | ₹133 Cr | ₹1509 Cr | ₹1369 Cr | ₹1207 Cr | ₹1189 Cr | ₹1016 Cr | ₹872 Cr | ₹741 Cr | ₹688 Cr | ₹558 Cr | ₹458 Cr | ₹374 Cr |
| ₹692 Cr | ₹708 Cr | ₹620 Cr | ₹573 Cr | ₹584 Cr | ₹670 Cr | ₹858 Cr | ₹1256 Cr | ₹1386 Cr | ₹1497 Cr | ₹1637 Cr | ₹1795 Cr | ₹2584 Cr | ₹2074 Cr | ₹1742 Cr | ₹1603 Cr | ₹2008 Cr | ₹1540 Cr | ₹1105 Cr | ₹990 Cr |
| ₹341 Cr | ₹64 Cr | ₹16 Cr | ₹46 Cr | ₹10 Cr | ₹7 Cr | ₹15 Cr | ₹264 Cr | ₹257 Cr | ₹274 Cr | ₹265 Cr | ₹267 Cr | ₹332 Cr | ₹329 Cr | ₹322 Cr | ₹469 Cr | ₹547 Cr | ₹620 Cr | ₹553 Cr | ₹270 Cr |
| ₹67 Cr | ₹60 Cr | ₹46 Cr | ₹44 Cr | ₹45 Cr | ₹40 L | ₹34 L | ₹47 L | ₹1 Cr | ₹96 L | ₹81 L | ₹81 L | ₹95 L | ₹81 L | ₹81 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹67 Cr | ₹60 Cr | ₹46 Cr | ₹44 Cr | ₹45 Cr | ₹40 L | ₹34 L | ₹47 L | ₹1 Cr | ₹96 L | ₹81 L | ₹81 L | ₹95 L | ₹81 L | ₹81 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹156 Cr | ₹131 Cr | ₹66 Cr | ₹60 Cr | ₹74 Cr | ₹9 Cr | ₹7 Cr | ₹765 Cr | ₹778 Cr | ₹687 Cr | ₹681 Cr | ₹683 Cr | ₹577 Cr | ₹221 Cr | ₹296 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2 L | ₹2 L | ₹2 L | ₹0 | ₹74,000 | ₹1 L | ₹0 | ₹10 Cr | ₹10 Cr | ₹6 Cr | ₹12 Cr | ₹23 Cr | ₹28 Cr | ₹37 Cr | ₹13 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹1329 Cr | ₹980 Cr | ₹763 Cr | ₹724 Cr | ₹713 Cr | ₹687 Cr | ₹891 Cr | ₹2310 Cr | ₹2446 Cr | ₹2479 Cr | ₹2611 Cr | ₹2783 Cr | ₹3550 Cr | ₹2685 Cr | ₹2384 Cr | ₹2072 Cr | ₹2554 Cr | ₹2160 Cr | ₹1658 Cr | ₹1261 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹15 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹81 L | ₹81 L | ₹81 L | ₹8 L | ₹8 L |
| ₹372 Cr | ₹457 Cr | ₹264 Cr | ₹229 Cr | ₹173 Cr | ₹153 Cr | ₹142 Cr | ₹170 Cr | ₹194 Cr | ₹211 Cr | ₹242 Cr | ₹252 Cr | ₹506 Cr | ₹669 Cr | ₹618 Cr | ₹423 Cr | ₹768 Cr | ₹649 Cr | ₹612 Cr | ₹448 Cr |
| ₹381 Cr | ₹353 Cr | ₹196 Cr | ₹215 Cr | ₹171 Cr | ₹136 Cr | ₹68 Cr | ₹120 Cr | ₹120 Cr | ₹203 Cr | ₹310 Cr | ₹257 Cr | ₹179 Cr | ₹113 Cr | ₹513 Cr | ₹737 Cr | ₹673 Cr | ₹538 Cr | ₹383 Cr | ₹349 Cr |
| ₹84 Cr | ₹201 Cr | ₹267 Cr | ₹31 Cr | ₹8 Cr | ₹20 Cr | ₹174 Cr | ₹326 Cr | ₹306 Cr | ₹257 Cr | ₹315 Cr | ₹391 Cr | ₹23 Cr | ₹177 Cr | ₹201 Cr | ₹335 Cr | ₹53 Cr | ₹31 Cr | ₹119 Cr | ₹16 Cr |
| ₹17 Cr | ₹11 Cr | ₹7 Cr | ₹4 Cr | ₹13 Cr | ₹10 Cr | ₹22 Cr | ₹12 Cr | ₹20 Cr | ₹9 Cr | ₹117 Cr | ₹80 L | ₹14 Cr | ₹16 Cr | ₹9 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr |
| ₹75 Cr | ₹76 Cr | ₹57 Cr | ₹23 Cr | ₹20 Cr | ₹96 Cr | ₹164 Cr | ₹140 Cr | ₹40 Cr | ₹198 Cr | ₹268 Cr | ₹378 Cr | ₹378 Cr | ₹278 Cr | ₹185 Cr | ₹201 Cr | ₹97 Cr | ₹102 Cr | ₹116 Cr | ₹93 Cr |
| ₹929 Cr | ₹1097 Cr | ₹791 Cr | ₹501 Cr | ₹384 Cr | ₹429 Cr | ₹569 Cr | ₹767 Cr | ₹679 Cr | ₹879 Cr | ₹1251 Cr | ₹1278 Cr | ₹1101 Cr | ₹1253 Cr | ₹1526 Cr | ₹1701 Cr | ₹1596 Cr | ₹1324 Cr | ₹1233 Cr | ₹908 Cr |
| ₹438 Cr | ₹589 Cr | ₹531 Cr | ₹129 Cr | ₹144 Cr | ₹287 Cr | ₹394 Cr | -₹1578 Cr | -₹1334 Cr | -₹662 Cr | -₹86 Cr | ₹155 Cr | -₹2105 Cr | -₹298 Cr | -₹463 Cr | ₹729 Cr | ₹740 Cr | ₹590 Cr | ₹568 Cr | ₹640 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹84 Cr | ₹0 | ₹0 | ₹0 |
| ₹2258 Cr | ₹2077 Cr | ₹1554 Cr | ₹1225 Cr | ₹1111 Cr | ₹1237 Cr | ₹1460 Cr | ₹3077 Cr | ₹3125 Cr | ₹3358 Cr | ₹3862 Cr | ₹4061 Cr | ₹4651 Cr | ₹3938 Cr | ₹3910 Cr | ₹3774 Cr | ₹4234 Cr | ₹3484 Cr | ₹2891 Cr | ₹2169 Cr |
| ₹993 | ₹987 | ₹231 | ₹169 | ₹159 | ₹160 | ₹188 | -₹79 | -₹89 | -₹44 | ₹6 | ₹39 | ₹54 | ₹161 | ₹152 | ₹133 | ₹78 | ₹101 | ₹74 | ₹120 |
| ₹993 | ₹987 | ₹231 | ₹169 | ₹159 | ₹160 | ₹188 | -₹79 | -₹89 | -₹44 | ₹6 | ₹39 | ₹54 | ₹161 | ₹152 | ₹133 | ₹78 | ₹101 | ₹74 | ₹120 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Sep 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹10 Cr | ₹122 Cr | ₹89 Cr | ₹46 Cr | -₹2 Cr | -₹117 Cr | -₹131 Cr | ₹69 Cr | -₹399 Cr | -₹452 Cr | -₹296 Cr | -₹243 Cr | -₹573 Cr | ₹75 Cr | ₹172 Cr | ₹470 Cr | -₹34 Cr | ₹229 Cr | ₹93 Cr |
| ₹42 Cr | ₹40 Cr | ₹44 Cr | ₹51 Cr | ₹37 Cr | ₹172 Cr | ₹140 Cr | ₹57 Cr | ₹453 Cr | ₹582 Cr | ₹490 Cr | ₹1006 Cr | ₹661 Cr | ₹334 Cr | ₹215 Cr | -₹557 Cr | ₹200 Cr | ₹132 Cr | ₹189 Cr |
| ₹71 Cr | -₹95 Cr | -₹8 Cr | -₹79 Cr | ₹60 Cr | -₹37 Cr | ₹62 Cr | -₹110 Cr | -₹38 Cr | ₹187 Cr | ₹18 Cr | -₹669 Cr | ₹79 Cr | ₹357 Cr | ₹7 Cr | ₹119 Cr | -₹117 Cr | -₹118 Cr | -₹184 Cr |
| ₹123 Cr | ₹67 Cr | ₹125 Cr | ₹19 Cr | ₹94 Cr | ₹19 Cr | ₹70 Cr | ₹16 Cr | ₹16 Cr | ₹317 Cr | ₹212 Cr | ₹94 Cr | ₹168 Cr | ₹766 Cr | ₹393 Cr | ₹32 Cr | ₹49 Cr | ₹243 Cr | ₹97 Cr |
| ₹126 Cr | ₹51 Cr | ₹126 Cr | ₹18 Cr | ₹92 Cr | ₹24 Cr | ₹81 Cr | ₹12 Cr | ₹9 Cr | ₹317 Cr | ₹212 Cr | -₹369 Cr | ₹168 Cr | ₹737 Cr | ₹332 Cr | -₹34 Cr | ₹46 Cr | ₹210 Cr | ₹96 Cr |
| -₹277 Cr | -₹36 Cr | -₹312 Cr | -₹31 Cr | ₹113 Cr | ₹67 Cr | ₹167 Cr | ₹45 Cr | -₹28 Cr | -₹9 Cr | -₹1 Cr | ₹1334 Cr | -₹986 Cr | -₹293 Cr | -₹367 Cr | ₹1413 Cr | -₹477 Cr | -₹545 Cr | -₹477 Cr |
| ₹137 Cr | ₹2 Cr | ₹167 Cr | ₹31 Cr | -₹217 Cr | -₹165 Cr | -₹250 Cr | -₹30 L | ₹33 Cr | -₹366 Cr | -₹286 Cr | -₹597 Cr | ₹664 Cr | -₹480 Cr | -₹78 Cr | -₹1077 Cr | ₹431 Cr | ₹247 Cr | ₹485 Cr |
| -₹14 Cr | ₹17 Cr | -₹19 Cr | ₹18 Cr | -₹11 Cr | -₹74 Cr | -₹2 Cr | ₹57 Cr | ₹15 Cr | -₹58 Cr | -₹76 Cr | ₹367 Cr | -₹153 Cr | -₹36 Cr | -₹113 Cr | ₹302 Cr | ₹2 L | -₹88 Cr | ₹104 Cr |
| ₹21 Cr | ₹4 Cr | ₹23 Cr | ₹4 Cr | ₹16 Cr | ₹90 Cr | ₹92 Cr | ₹35 Cr | ₹21 Cr | ₹315 Cr | ₹391 Cr | ₹23 Cr | ₹177 Cr | ₹213 Cr | ₹326 Cr | ₹24 Cr | ₹24 Cr | ₹112 Cr | ₹8 Cr |
| ₹7 Cr | ₹21 Cr | ₹4 Cr | ₹23 Cr | ₹4 Cr | ₹16 Cr | ₹90 Cr | ₹92 Cr | ₹35 Cr | ₹257 Cr | ₹315 Cr | ₹391 Cr | ₹23 Cr | ₹177 Cr | ₹213 Cr | ₹326 Cr | ₹24 Cr | ₹24 Cr | ₹112 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 5 out of 9 oscillators
RSI
59.44Buy
STOCH %K
84.31Sell
MACD Level(12,26)
4.34Buy
Ultimate Oscillator
49.05Sell
Aroon Oscillator
-42.00Sell
BOP
0.45Buy
CCI
154.18Sell
Williams %R
-15.69Sell
Momentum
113.10Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
923.49Buy
SMA 9
912.55Buy
EMA 21
909.47Buy
SMA 21
881.37Buy
EMA 50
926.28Buy
SMA 50
945.30Buy
EMA 200
874.44Buy
SMA 200
825.53Buy
WMA 20
902.82Buy
Pivot
Pivot
Classic
Resistance 5
1085.10
Resistance 4
1050.40
Resistance 3
1015.70
Resistance 2
981.00
Resistance 1
964.80
Pivot
946.30
Support 1
930.10
Support 2
911.60
Support 3
876.90
Support 4
842.20
Support 5
807.50
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 74.45% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% |
| 0.93% | 0.80% | 0.87% | 1.17% | 1.56% | 1.39% |
| 0.56% | 0.82% | 0.81% | 1.38% | 1.00% | 0.85% |
| 16.88% | 19.93% | 19.43% | 18.01% | 18.04% | 18.58% |
| 7.18% | 8.61% | 9.05% | 9.60% | 9.56% | 9.34% |
Bulk & block deals
Name
Uti Mutual Fund
Uti Mutual Fund
Dhanuka Laboratories Limited
Polaris Banyan Holding Private Ltd
Adurjee And Bros Pvt Ltd
Fortune Intercontinental Pvt Ltd
Serum Institute Of India Private Limited
Fortune Intercontinental Pvt Ltd
Serum Institute Of India Private Limited
Serum Institute Of India Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 30 May 2025 | Purchase | 22.55 Cr | ₹615.37 | 3.67 L | Bulk | 0.722621 | NSE |
| 28 Nov 2023 | Purchase | 25.41 Cr | ₹571 | 4.45 L | Bulk | 0.743088 | BSE |
| 28 Nov 2023 | Sell | 74.27 Cr | ₹571.28 | 13 L | Bulk | 2.17082 | BSE |
| 10 Jan 2018 | Purchase | 1.27 Cr | ₹24.02 | 5.29 L | Bulk | 0.883357 | NSE |
| 04 Jan 2018 | Sell | 1.45 Cr | ₹21.10 | 6.85 L | Bulk | 1.143668 | NSE |
| 03 Jan 2018 | Sell | 95.41 L | ₹20.30 | 4.70 L | Bulk | 0.784835 | BSE |
| 03 Jan 2018 | Sell | 2.64 Cr | ₹20.10 | 13.12 L | Bulk | 2.191693 | NSE |
| 03 Jan 2018 | Sell | 1.32 Cr | ₹20.10 | 6.58 L | Bulk | 1.098954 | NSE |
| 19 Dec 2017 | Sell | 1.37 Cr | ₹19.37 | 7.06 L | Bulk | 1.178341 | NSE |
| 18 Dec 2017 | Sell | 1.39 Cr | ₹18.55 | 7.50 L | Bulk | 1.252396 | NSE |
Insider trading & SAST
Client name
Dhanuka Laboratories Limited
Dhanuka Laboratories Limited
M/Sdhanuka Laboratories Ltd
Dhanuka Laboratories Ltd
Dhanuka Laboratories Ltd
Orchid Health Care Pvt. Ltd. (Ohpl)
K Raghavendra Rao
R Vijayalakashmi
R Vijayalakshmi
R Vijayalakshmi
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 1.20 Cr | 19 Jan 2022 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Non disposal undertaking | — | — | 0 | — | 80 L | 24 Jan 2022 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 1.20 Cr | 30 Jun 2021 | Creation | 1,20,00,022 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 1.20 Cr | 30 Jun 2021 | Creation | 1,20,00,022 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Non disposal undertaking | — | — | 0 | — | 80 L | 30 Jun 2021 | Creation | 2,00,00,037 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 37.02 L | 08 Feb 2018 | Creation | 1,94,08,575 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 20 K | 29 Mar 2017 | Invocation | 10,65,173 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 55.40 K | 28 Mar 2017 | Invocation | 23,89,755 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 1 L | 16 Mar 2017 | Invocation | 24,45,155 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 1 L | 07 Mar 2017 | Invocation | 25,45,155 | SAST | Reg31 | — |
Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
Orchid Pharma (Orchid) established as an export-oriented unit (EOU) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research manufacturing
Corporate Actions
Date
Type
Details
Company details
Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Orchid Pharma Share Price
960.40+0.00 (+1.24%)
+10.85% past 1 Year
News
1 of 20
ResultORCHPHARMA14 Nov 2026
NULL
Orchid Pharma Purchases Kancheepuram Land And Ends DBS Bank Lease
Stock NewsORCHPHARMA23 Sept 2026
Orchid Pharma has purchased land situated at Patibulum Village in Kancheepuram District, Tamil Nadu, and finalized the closure of its lease arrangement with DBS Bank India Limited. The transaction provides Orchid Pharma with permanent ownership rights over the property and ends DBS Bank's rights and interest in the asset.
The purchase resolves the earlier lease structure and provides greater certainty over the company's property ownership. No transaction value, land area, financing details, or quantified earnings impact were disclosed. The development may reduce continuing lease-related uncertainty and support balance sheet clarity, although its direct effect on revenue and profitability cannot be quantified from the available information.
Orchid Pharma to commence 7-ACA plant operations by March 2027
Stock NewsORCHPHARMA24 Aug 2026
Orchid Pharma has announced that its planned 7-ACA manufacturing plant is expected to begin operations by March 2027. The facility is linked to a backward-integration project for 7-ACA, a key intermediate in cephalosporin antibiotics, and is understood to be located in Jammu to leverage cost and infrastructure advantages. Once operational, the plant is likely to enhance Orchid Pharma's control over a critical part of its supply chain, potentially improving raw material security and operational efficiencies in its antibiotics portfolio. The company has indicated that commercial operations from this facility would start around March 2027, with meaningful revenue contribution expected from the subsequent financial year, suggesting a phased ramp-up in capacity utilization and product offtake.
Strategically, the 7-ACA project is positioned to provide cost benefits through lower electricity expenses and available regional incentives, which could support margin improvement over time. Backward integration into key intermediates typically reduces dependence on external suppliers, mitigates price volatility risks and strengthens bargaining power, which may be supportive for Orchid Pharma's long-term earnings profile once the plant stabilizes. In addition, management commentary has highlighted that the 7-ACA market has exhibited price stability over the past decade, which, combined with internal sourcing, may provide better visibility on input costs. While there is no immediate impact on near-term financials, the initiative is a medium- to long-term capacity and efficiency enhancement, and the market will likely track execution timelines, commissioning milestones and early utilization trends as the plant approaches its March 2027 operational target.
Orchid Pharma inks exclusive Exblifep licensing deal with Russian firm Pharmasyntez
Stock NewsORCHPHARMA7 Jul 2026
Orchid Pharma has signed an exclusive licensing and commercialisation agreement with Russian pharmaceutical company Pharmasyntez for its antibiotic product Exblifep in the Russian market. The partnership is expected to have a total value of around Rs 17.80 crores over a 10-year period, indicating a long-term revenue visibility from this out-licensing arrangement. The deal structure, as communicated, suggests milestone and/or royalty-linked income streams rather than an upfront one-time payment, which could allow Orchid Pharma to benefit from Russia-specific sales ramp-up over time.
Exblifep is part of Orchid Pharma’s pipeline of novel and differentiated anti-infective therapies, where the company has been actively pursuing global licensing opportunities across key geographies including the US, Japan, Russia, Latin America and Southeast Asia. The exclusive agreement with Pharmasyntez strengthens Orchid Pharma’s presence in Russia by leveraging a local partner with established manufacturing, regulatory and distribution capabilities in that market. For Pharmasyntez, the tie-up provides access to an innovative antibiotic, potentially expanding its portfolio of socially important drugs and supporting its strategy of bringing new therapies to Russian patients.
From a financial and strategic perspective, the partnership has the potential to modestly enhance Orchid Pharma’s earnings over the medium to long term, with limited capital expenditure or balance sheet risk, as commercial execution and local investments are expected to be driven primarily by Pharmasyntez. While the absolute quantum of Rs 17.80 crores spread over 10 years is not large in the context of the broader Indian pharmaceuticals sector, it is incrementally positive for Orchid Pharma’s monetisation of its research assets and could support valuation narratives around its specialty anti-infective franchise. Market impact, however, is likely to be stock-specific and relatively contained rather than index-moving.
Orchid Pharma projects significant global sales potential for key antibiotic combo
Stock NewsORCHPHARMA16 Jun 2026
Orchid Pharma has indicated a sizeable global sales opportunity for its antibiotic combination Enmetazobactam-Cefepime, estimating potential sales in the range of $100.00 crores to $200.00 crores. This projection underscores the company’s focus on complex hospital-focused anti-infective therapies and highlights the commercial promise of this specific drug combination in international markets. While the company has not disclosed a specific timeline for achieving this sales band, the guidance signals management’s confidence in demand visibility, underlying clinical differentiation, and addressable market size for resistant bacterial infections.
The Enmetazobactam-Cefepime combination is positioned for serious infections where resistance to existing therapies is a growing concern, which could support healthy pricing and margin profile upon broader market penetration. If the guided sales range is achieved over the medium term, it could meaningfully enhance Orchid Pharma’s revenue scale, improve operating leverage, and potentially support higher research and development investments in its specialty injectable and antibiotic pipeline. The development may also help Orchid Pharma strengthen its global partnerships and out-licensing opportunities, given that such complex anti-infective products often require collaborations for registration, marketing, and distribution across key regulated and semi-regulated markets.
From an equity perspective, the announcement is a positive data point for earnings visibility, even though near-term financial impact will depend on regulatory milestones, launch timing across geographies, and competitive responses from other anti-infective players. There is no explicit information in the given context on current stock price movement, valuation, or incremental capital expenditure requirements linked to this product. However, the quantified global sales potential itself is likely to be read constructively by the market, as it offers investors a clearer view of the long-run contribution that Enmetazobactam-Cefepime could make to Orchid Pharma’s overall business mix.
Orchid Pharma nears US licensing deal for novel antibiotic candidate
Stock NewsORCHPHARMA16 Jun 2026
Orchid Pharma is reported to be in advanced-stage discussions to secure a US licensing deal for its novel antibiotic asset. The development indicates that negotiations with a potential partner or licensee in the US market have progressed meaningfully, though final execution and commercial terms have not yet been disclosed. The focus on a novel antibiotic suggests that the underlying molecule is likely differentiated versus existing anti-infective therapies, which, if successfully commercialised, can enhance the company’s specialty pharma profile and global footprint in critical-care or hospital-focused anti-infective segments.
A successful US licensing agreement would typically involve upfront payments, potential milestone-linked payouts, and royalties on future sales, which can materially improve Orchid Pharma’s revenue visibility and profitability over the medium term. The partnership structure could also reduce the company’s own commercialisation and regulatory burden in the US, as the licensee would generally take responsibility for clinical development completion, regulatory interactions with US FDA, and go-to-market execution. For Orchid Pharma, monetising a novel antibiotic through licensing rather than fully self-commercialising can be capital efficient and can help de-risk its balance sheet while still retaining economic upside from the asset’s success.
If concluded on favourable terms, the proposed licensing deal can strengthen Orchid Pharma’s positioning in the global anti-infective space and potentially support incremental investments in its R&D pipeline. The news is stock-specific and company-level rather than sector-wide, so any impact on broader banking or index performance is expected to be limited. However, at the individual stock level, progress towards a US licensing transaction for a novel antibiotic is a strategically positive signal that the market may interpret as value accretive, subject to eventual deal size, structure, and regulatory outcomes.
Orchid Pharma gains NCLT nod for merger with Dhanuka Lab to scale operations
Stock NewsORCHPHARMA12 Jun 2026
Orchid Pharma has received approval from the National Company Law Tribunal (NCLT) for the merger of Dhanuka Lab with the company. The transaction is positioned as a strategic consolidation aimed at creating a larger, fully integrated pharmaceutical platform. Post-merger, the combined entity is expected to target annual revenues in the range of about Rs 1,400–1,500 crores, indicating a meaningful step-up in scale versus a standalone profile. Management commentary around the proposal highlights operational synergies, better utilisation of manufacturing assets and stronger integration across the value chain as key drivers of the enlarged revenue potential.
On the profitability front, the merged operations are projected to generate EBITDA in the band of roughly Rs 200–250 crores, supported by cost savings, procurement efficiencies and improved product mix. These benefits are expected to flow from rationalisation of overlapping functions, optimisation of capacity, and enhanced bargaining power with both suppliers and distributors. A stronger combined market presence could also support better pricing power and deeper penetration across key therapeutic segments where Orchid Pharma and Dhanuka Lab have complementary strengths.
From an earnings perspective, the NCLT approval removes a key regulatory overhang and clears the path for management to begin formal integration, which is critical for realising the projected revenue and EBITDA outcomes. The enlarged scale, if executed as planned, can strengthen Orchid Pharma’s competitive positioning in the domestic formulations and active pharmaceutical ingredients space, and could potentially improve its ability to invest in research, product registrations and compliance. While detailed contours of integration timelines and capital structure impacts are not specified in the available update, the development represents an important corporate action that may support medium-term growth visibility and operating leverage for Orchid Pharma.
Orchid Pharma informs about investor presentation
Stock NewsORCHPHARMA26 May 2026
NULL
Orchid Pharma reports Profit after tax of 30.60 Crores, in the March 2026 quarter
ResultORCHPHARMA25 May 2026
NULL
Orchid Pharma Q4 EBITDA declines year-on-year with lower operating margin performance
ResultORCHPHARMA25 May 2026
Orchid Pharma reported a year-on-year decline in operating performance for the fourth quarter, as reflected in its EBITDA and margin metrics. Q4 EBITDA stood at Rs 29.00 crores compared with Rs 34.30 crores in the same quarter last year, indicating a contraction in absolute operating profit on a yearly basis. This suggests higher operating costs, weaker operating leverage, or an unfavourable product or geographic mix during the period compared to the previous year. The lower EBITDA also implies reduced internal cash generation capacity from core operations for the quarter under review.
EBITDA margin for Q4 came in at 12.20 percent versus 14.46 percent in the corresponding quarter of the prior year, marking a clear deterioration in operating profitability on a percentage basis. The compression in margin indicates that revenue growth, if any, has not been sufficient to offset cost pressures, or that pricing, input costs, or overheads have moved adversely relative to sales. From an investor perspective, sustained margin contraction can be a concern as it may point to competitive intensity, input cost inflation, or execution challenges that need to be monitored in subsequent quarters.
The available information does not provide details on revenue, PAT, or quarter-on-quarter trends, nor does it include management commentary, guidance, or any reference to market expectations or consensus estimates. There is also no data on stock price reaction, F&O positioning, or institutional flows linked to this result. As such, the interpretation is limited to the observed weakening in EBITDA and EBITDA margin on a year-on-year basis, which indicates a softer operational performance for Orchid Pharma in Q4 compared to the same period last year.
Orchid Pharma Q4 FY earnings: flat revenue, modest profit growth YoY
ResultORCHPHARMA25 May 2026
Orchid Pharma reported its Q4 standalone results with a modest year-on-year improvement in profitability while revenue remained flat. Q4 standalone net profit came in at Rs 30.60 crores compared with Rs 27.90 crores in the same quarter last year, indicating a small expansion in bottom line despite no change in the topline. On the revenue front, the company posted Q4 revenue of Rs 237.00 crores, exactly in line with Rs 237.00 crores reported in the year-ago quarter, suggesting stable sales performance without visible growth momentum on an annual comparison.
The combination of flat revenue and higher net profit implies some improvement in profitability levers such as cost optimization, product mix, or operational efficiency, although detailed margin data and EBITDA metrics are not provided in the available disclosure. In the absence of explicit guidance or management commentary, the sustainability of this profitability uptick into coming quarters cannot be assessed from the current information set. Similarly, there is no reference to one-off items, finance costs, tax effects, or other comprehensive income that might have influenced the net profit number, so the quality of earnings cannot be fully evaluated.
Street expectations, consensus estimates, and intra-day stock price reaction are not mentioned in the provided context, limiting visibility on how the market may immediately interpret these figures. From a fundamental read-through, the print appears operationally steady rather than transformational, with Orchid Pharma demonstrating the ability to protect profitability even in a no-growth revenue quarter. Overall, the Q4 snapshot portrays a stable earnings performance anchored by flat revenue and a marginally higher net profit on a year-on-year basis.
NCLT Rejects DBS Bank's Lease Rent Claim Against Orchid Pharma in CIRP Proceedings
Stock NewsORCHPHARMA11 Apr 2026
The National Company Law Tribunal (NCLT) has rejected DBS Bank's claim for lease rent pertaining to Orchid Pharma during its Corporate Insolvency Resolution Process (CIRP). The order was issued on April 2, 2026, and released on April 10, 2026.
This regulatory decision resolves a key creditor claim in the ongoing CIRP for Orchid Pharma, a pharmaceutical company listed on NSE/BSE. Rejection of the lease rent claim by DBS Bank, a significant financial institution, may streamline the resolution process by reducing potential liabilities or disputed obligations. Such outcomes in CIRP can positively influence creditor haircuts, asset valuation, and the feasibility of resolution plans, potentially aiding faster emergence from insolvency.
No specific quantum of the claim or immediate stock price reaction is detailed in the available information. The development pertains to corporate restructuring under IBC framework, impacting Orchid Pharma's balance sheet and future operations in the pharma sector.
Orchid Pharma Q3 FY2026 Results: Sharp EBITDA Decline and Consolidated Loss
ResultORCHPHARMA11 Feb 2026
Orchid Pharma Limited reported Q3 FY2026 (quarter ended December 31, 2025) results on February 11, 2026, revealing significant operational deterioration. On a standalone basis, total income declined to Rs 21,785.70 lakhs from Rs 22,727.97 lakhs YoY, representing a 4.1% decline. EBITDA contracted sharply to Rs 1.60 crores from Rs 26.40 crores YoY, a 93.9% YoY decline, with EBITDA margin compressing to 0.76% versus 12.13% previously. The company reported a pre-tax loss of Rs 582.43 lakhs for Q3 versus a profit of Rs 2,390.63 lakhs in the corresponding quarter last year.
On consolidated basis, Q3 total income was Rs 21,287.64 lakhs against Rs 21,734.25 lakhs YoY. The company reported a consolidated pre-tax loss of Rs 1,214.64 lakhs, significantly worse than standalone performance. For the nine-month period (April–December 2025), consolidated results showed a pre-tax loss of Rs 323.32 lakhs versus a profit of Rs 2,245.00 lakhs in the prior year period.
The deterioration was partially attributable to an exceptional item of Rs 711.27 lakhs related to incremental employee benefit liabilities following the implementation of the New Labour Codes effective November 21, 2025. Total expenses increased to Rs 21,656.86 lakhs from Rs 20,337.34 lakhs YoY. The auditors noted they did not review interim financial results of three US-based subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.), which reported nil revenue and nil net profit/loss.
On consolidated basis, Q3 total income was Rs 21,287.64 lakhs against Rs 21,734.25 lakhs YoY. The company reported a consolidated pre-tax loss of Rs 1,214.64 lakhs, significantly worse than standalone performance. For the nine-month period (April–December 2025), consolidated results showed a pre-tax loss of Rs 323.32 lakhs versus a profit of Rs 2,245.00 lakhs in the prior year period.
The deterioration was partially attributable to an exceptional item of Rs 711.27 lakhs related to incremental employee benefit liabilities following the implementation of the New Labour Codes effective November 21, 2025. Total expenses increased to Rs 21,656.86 lakhs from Rs 20,337.34 lakhs YoY. The auditors noted they did not review interim financial results of three US-based subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.), which reported nil revenue and nil net profit/loss.
Orchid Pharma Q3 FY2025 Consolidated Net Loss of Rs 12.60 Crores vs YoY Profit.
ResultORCHPHARMA11 Feb 2026
Orchid Pharma reported consolidated financial results for Q3 FY2025 (quarter ended December 31, 2025). Consolidated total income stood at Rs 212.88 crores, down from Rs 217.34 crores YoY. The company posted a net loss of Rs 12.60 crores, contrasting with a profit of Rs 20.80 crores in the previous year's corresponding quarter. Revenue was Rs 207.00 crores versus Rs 220.00 crores YoY.
On standalone basis, total income was Rs 217.86 crores compared to Rs 227.28 crores YoY. Profit/(loss) before tax was a loss of Rs 5.82 crores versus profit of Rs 23.91 crores YoY. An exceptional item of Rs 7.11 crores loss was recorded due to incremental liability from revised Labour Codes on past service costs. For nine months ended December 31, 2025, consolidated profit/(loss) before tax was a loss of Rs 3.23 crores against profit of Rs 22.45 crores prior year.
Auditors noted that interim financial results for certain US subsidiaries were not reviewed, with management reporting nil revenue and nil profit/loss for these entities. Board approved the unaudited limited reviewed results on February 11, 2026.[1]
Orchid Pharma reports Profit after tax of Rs -5.83 Crores, in the December 2025 quarter
ResultORCHPHARMA11 Feb 2026
NULL
Orchid Pharma aims for FY26 revenue growth with capacity, product pipeline, and Chennai plant commissioning.
Stock NewsORCHPHARMA11 Nov 2025
Orchid Pharma Limited, a key pharmaceutical player, has outlined a growth-focused strategy for FY26 and beyond. The company is targeting a 13% year-on-year increase in revenue, driven by an expansion in manufacturing capabilities and a robust new product pipeline across Cephalosporin and Carbapenem APIs. Orchid Pharma is commissioning a new plant in Chennai, expected to enhance API production by 25% and support greater penetration in export markets. Backward integration measures and a dedicated R&D pipeline, comprising eight new molecules, are central to this growth trajectory.
Investments include significant capital expenditure for expanding oral API capacity and establishing a new state-of-the-art injectables facility, projecting further scale and cost efficiency gains. The company is also advancing strategic projects such as the upcoming 7ACA facility in Jammu and the acquisition of assets in Europe to strengthen its global anti-infectives business. Orchid Pharma has reported improved financial health over FY23-FY25, with steady rises in operating income, PAT, and EBITDA, supported by low gearing and strong interest coverage ratios. While Q2 FY26 performance showed a temporary dip, the management expects volume-led growth and margin expansion into FY26–27, underpinned by the Chennai plant's commissioning and ongoing export market initiatives.
Investments include significant capital expenditure for expanding oral API capacity and establishing a new state-of-the-art injectables facility, projecting further scale and cost efficiency gains. The company is also advancing strategic projects such as the upcoming 7ACA facility in Jammu and the acquisition of assets in Europe to strengthen its global anti-infectives business. Orchid Pharma has reported improved financial health over FY23-FY25, with steady rises in operating income, PAT, and EBITDA, supported by low gearing and strong interest coverage ratios. While Q2 FY26 performance showed a temporary dip, the management expects volume-led growth and margin expansion into FY26–27, underpinned by the Chennai plant's commissioning and ongoing export market initiatives.
Orchid Pharma reports Profit after tax of 2.23 Crores, in the September 2025 quarter
ResultORCHPHARMA11 Nov 2025
NULL
Orchid Pharma reports Q2 FY25 earnings with EBITDA of Rs 37.5 crores; revenue rose 12% YoY.
ResultORCHPHARMA11 Nov 2025
Orchid Pharma Limited announced its Q2 FY25 earnings, covering the period ended September 30, 2025. The company reported quarterly revenue of Rs 222.7 crores, marking a 12% year-on-year increase driven by momentum in business development and a successful customer base recovery. EBITDA for the quarter stood at Rs 37.5 crores, reflecting continued emphasis on efficient cost control, productivity, and operational improvements.
The launch of ORBLICEF—India's first innovator drug commercialized in the EU and approved in the US—has commenced in the Indian market, with initial microbiological results reported as promising. Sales of Enmetazobactam also began recently in the EU; management highlights expectations for growth from both domestic and international segments. The sterile versus oral business split remains at 30% and 70%, respectively, with domestic revenues contributing approximately 20%.
While the company reported strong cumulative performance, management cautioned that Orchid should not be viewed from a sequential quarter-on-quarter perspective. The sequential revenue decline of approximately 8.9% was attributed to the prior quarter’s high growth rate, which was not expected to continue at the same pace. Key projects, such as capacity enhancement, have already been commissioned ahead of schedule and are set to contribute to near-term sales. Deficiencies noted in the US FDA filing for Ceftazidime-Avibactam are being addressed and re-filing is anticipated within the quarter. The company's forward-looking commentary remains constructive, supported by product launches and regulatory updates.
The launch of ORBLICEF—India's first innovator drug commercialized in the EU and approved in the US—has commenced in the Indian market, with initial microbiological results reported as promising. Sales of Enmetazobactam also began recently in the EU; management highlights expectations for growth from both domestic and international segments. The sterile versus oral business split remains at 30% and 70%, respectively, with domestic revenues contributing approximately 20%.
While the company reported strong cumulative performance, management cautioned that Orchid should not be viewed from a sequential quarter-on-quarter perspective. The sequential revenue decline of approximately 8.9% was attributed to the prior quarter’s high growth rate, which was not expected to continue at the same pace. Key projects, such as capacity enhancement, have already been commissioned ahead of schedule and are set to contribute to near-term sales. Deficiencies noted in the US FDA filing for Ceftazidime-Avibactam are being addressed and re-filing is anticipated within the quarter. The company's forward-looking commentary remains constructive, supported by product launches and regulatory updates.
Orchid Pharma reports Q2 FY25 consolidated net loss of Rs 5.70 crores versus Rs 25.60 crores profit year-on-year.
ResultORCHPHARMA11 Nov 2025
Orchid Pharma Limited (NSE: ORCHPHARMA), a leading Indian pharmaceutical manufacturer, announced its Q2 FY25 consolidated financial results, posting a net loss of Rs 5.70 crores as compared to a net profit of Rs 25.60 crores in the corresponding quarter of the previous fiscal year. The performance marks a significant decline in profitability on a year-on-year basis.
Despite challenging quarterly earnings, the company reported quarterly revenue of Rs 222.7 crores and highlighted the successful domestic launch of ORBLICEF, an innovative drug combining Enmetazobactam and Cefepime. The company also commenced sales of Enmetazobactam in the EU, with initial volumes still ramping up, while awaiting further developments in the US market.
Operational highlights for the period include successful commissioning of a small-capacity enhancement project ahead of schedule, 30% sterile and 70% oral business mix, and ongoing expansion in branded formulations and molecule launches in India. The management emphasized that cumulative half-year results reflect an overall positive sales momentum and EBITDA growth, but acknowledged that sequential quarter-on-quarter performance may present volatility due to varying product cycles.
Despite challenging quarterly earnings, the company reported quarterly revenue of Rs 222.7 crores and highlighted the successful domestic launch of ORBLICEF, an innovative drug combining Enmetazobactam and Cefepime. The company also commenced sales of Enmetazobactam in the EU, with initial volumes still ramping up, while awaiting further developments in the US market.
Operational highlights for the period include successful commissioning of a small-capacity enhancement project ahead of schedule, 30% sterile and 70% oral business mix, and ongoing expansion in branded formulations and molecule launches in India. The management emphasized that cumulative half-year results reflect an overall positive sales momentum and EBITDA growth, but acknowledged that sequential quarter-on-quarter performance may present volatility due to varying product cycles.
Orchid Pharma: Co Aims To Cut Costs And Maintain Margins Due To Weak Sales; Using Api Portfolio, Export Chances, And Efficiency To Boost Medium-Term Revenue And Profit Growth. ??
Stock NewsORCHPHARMA12 Aug 2025
Orchid Pharma: Co Aims To Cut Costs And Maintain Margins Due To Weak Sales; Using Api Portfolio, Export Chances, And Efficiency To Boost Medium-Term Revenue And Profit Growth. ??

